Visit our reviews page to see a complete list of reviews in the immunology of infectious disease research field.
HIV-Positive Children and Adolescents: Added Benefit of Rilpivirine Not Proven
The German Institute for Quality and Efficiency in Health Care examined in an early benefit assessment whether rilpivirine has an added benefit for HIV-1-infected children and adolescents in comparison with the appropriate comparator therapy, i.e. the drug efavirenz in combination with abacavir plus lamivudine. According to the findings, such an added benefit of rilpivirine is not proven. [German Institute for Quality and Efficiency in Health Care] Press Release
Janssen to Unveil New Hepatitis B and C Data
Janssen Sciences Ireland UC announced it will present thirteen abstracts featuring new data on an investigational regimen for treatment of hepatitis B virus and approved and investigational regimens for the treatment of hepatitis C virus. [Press release from Janssen Sciences Ireland UC discussing research to be presented at the International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL), Barcelona] Press Release